Design of an in vivo cleavable disulfide linker in recombinant fusion proteins

被引:52
作者
Chen, Xiaoying [1 ]
Bai, Yun [1 ]
Zaro, Jennica L. [1 ]
Shen, Wei-Chiang [1 ]
机构
[1] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA
基金
美国国家卫生研究院;
关键词
recombinant fusion protein; disulfide linker; cleavable linker; COLONY-STIMULATING FACTOR; INSULIN-TRANSFERRIN CONJUGATE; CACO-2; CELLS; STABILITY; ANTIBODIES; ISOMERASE; MEMBRANE; DELIVERY; RAT;
D O I
10.2144/000113450
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In order to achieve optimal biological activity and desired pharmacokinetic profiles, a dithiocyclopeptide linker was designed for in vivo release of protein domains from a recombinant fusion protein. This novel in vivo cleavable disulfide linker, based on a dithiocyclopeptide containing a thrombin-sensitive sequence and an intramolecular disulfide bond, was inserted between transferrin and granulocyte colony-stimulating factor (G-CSF) recombinant fusion protein domains. After expression of the fusion protein, G-C-T, from HEK293 cells, thrombin treatment in vitro generated a fusion protein linked via a reversible disulfide bond that was quickly cleaved in vivo, separating the protein domains. After release from the fusion protein, free G-CSF exhibited an improved biological activity in a cell proliferation assay. Although reversible disulfide bonds are commonly used in protein chemical conjugation methods, to our knowledge this report is the first example of the construction of a recombinant fusion protein with a disulfide linkage for the release of the functional domain. This linker design can be adapted to diverse recombinant fusion proteins in which in vivo separation of protein domains is required to achieve an improved therapeutic effect and a desirable pharmacokinetic profile and biodistribution of the functional domain.
引用
收藏
页码:513 / +
页数:5
相关论文
共 23 条
[1]   Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats [J].
Amet, Nurmamet ;
Wang, Wei ;
Shen, Wei-Chiang .
JOURNAL OF CONTROLLED RELEASE, 2010, 141 (02) :177-182
[2]   Insertion of the Designed Helical Linker Led to Increased Expression of Tf-Based Fusion Proteins [J].
Amet, Nurmamet ;
Lee, Hsin-Fang ;
Shen, Wei-Chiang .
PHARMACEUTICAL RESEARCH, 2009, 26 (03) :523-528
[3]   Design of the linkers which effectively separate domains of a bifunctional fusion protein [J].
Arai, R ;
Ueda, H ;
Kitayama, A ;
Kamiya, N ;
Nagamune, T .
PROTEIN ENGINEERING, 2001, 14 (08) :529-532
[4]   A time- and cost-efficient system for high-level protein production in mammalian cells [J].
Aricescu, A. Radu ;
Lu, Weixian ;
Jones, E. Yvonne .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2006, 62 :1243-1250
[5]   New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability [J].
Arpicco, S ;
Dosio, F ;
Brusa, P ;
Crosasso, P ;
Cattel, L .
BIOCONJUGATE CHEMISTRY, 1997, 8 (03) :327-337
[6]   Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent [J].
Bai, Y ;
Ann, DK ;
Shen, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (20) :7292-7296
[7]   Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization [J].
Bai, Yun ;
Shen, Wei-Chiang .
PHARMACEUTICAL RESEARCH, 2006, 23 (09) :2116-2121
[8]   GLUTATHIONE METABOLISM AND ITS ROLE IN HEPATOTOXICITY [J].
DELEVE, LD ;
KAPLOWITZ, N .
PHARMACOLOGY & THERAPEUTICS, 1991, 52 (03) :287-305
[9]   Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink [J].
Hem, A ;
Smith, AJ ;
Solberg, P .
LABORATORY ANIMALS, 1998, 32 (04) :364-368
[10]   INVIVO ADMINISTRATION OF LYMPHOCYTE-SPECIFIC MONOCLONAL-ANTIBODIES IN NONHUMAN-PRIMATES - INVIVO STABILITY OF DISULFIDE-LINKED IMMUNOTOXIN CONJUGATES [J].
LETVIN, NL ;
GOLDMACHER, VS ;
RITZ, J ;
YETZ, JM ;
SCHLOSSMAN, SF ;
LAMBERT, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (03) :977-984